{
    "nctId": "NCT05607017",
    "briefTitle": "Losartan in Prevention of Radiation-Induced Heart Failure",
    "officialTitle": "The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Extracellular Volume (ECV) of Myocardial Fibrosis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n-\\>18 years of age\n\n* Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)\n* Prior chemotherapy is permitted\n* Patients must have Left-sided Breast Cancer\n* Ability to understand and the willingness to sign a written informed consent document\n* No contraindication to MRI\n\nExclusion Criteria:\n\n* Person who is pregnant or breastfeeding.\n* Patient unable to swallow oral medication.\n* Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity\n* Patients already receiving ACE/ARBs.\n* Patients with a history of allergic reactions to Losartan biosimilars.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}